Our technologies

Medical Devices

Device and method for force measurement in simulated minimal invasive surgery

Available For: LicensingSummaryA training device for minimally invasive surgery with built-in force sensing.The Technology and its Advantages The demand for ‘minimally invasive’, ‘laparoscopic’ or ‘key-hole’ surgery techniques has increased in recent years driven by factors such as increasing healthcare costs, rising focus on patient safety and the availability of new technologies. Whilst the demand has

More info »

Biopharm

LipoGlucoCEST - Novel Imaging Agents for GlucoCEST

Available For: LicensingSummaryGlucoCEST is a magnetic resonance imaging (MRI) technique that enables visualisation of natural, non-radioactive glucose that can be used in cancer diagnosis. However, this technique has limitations due to interactions with the body glucose sensing system. To solve this problem, researchers at UCL Institute of Neurology have developed a novel set of imaging

More info »

Biopharm

New lentiviral platform eliminating packaging sequences from the transcribed DNA region

Available for: Exclusive/Non-exclusive LicensingSummaryAll lentiviral vectors described to date contain packaging sequences necessary for the viral RNA genome to be assembled into viral particles. These sequences are unnecessarily reverse transcribed into DNA and permanently integrate into target cells. The researchers at UCL Institute of Child Health have developed a lentiviral platform which does not reverse

More info »

Biopharm

Treatment of fibrosis with ALDH inhibitors

Available for: Exclusive LicensingSummaryFibrosis is the formation of excess fibrous connective tissue in response to injury and inflammation. If it happens in response to injury it is also referred to as scarring. Fibrosis is associated with conditions such as cystic fibrosis, cirrhosis, mucous membrane pemphigoid (MMP), pulmonary fibrosis and scleroderma. It is also a consequence

More info »

Biopharm

Novel Therapy for Polycystic Kidney Disease (PKD)

Available for: Exclusive/Non-Exclusive LicensingSummaryPolycystic kidney disease is the most common inherited cause of kidney failure, affecting 1 in 1000 adults and children worldwide. It is characterized by the growth of multiple cysts leading to loss of normal kidney structure and functions and often results in end-stage renal disease. The researchers at UCL Institute of Child

More info »

Biopharm

H4R antagonists for uveitis and other inflammatory diseases

Available For: Exclusive LicensingSummaryHistamine is a pleiotropic mediator involved in a variety of physiological processes including neurotransmission, endocrine and vascular processes. It also plays a key role in inflammation and binding to one of its four receptors (H1R-H4R). Researchers at UCL Institute of Ophthalmology have shown that targeting H4R receptor in the central nervous system

More info »

Biopharm

Formulations for the Prevention of Neural Tube Defects

Available for: LicenseSummaryExploring ways to prevent birth defects, researchers at the UCL Institute of Child Health have discovered novel supplements that if taken in pregnancy can reduce the chance of the baby having neural tube defects such as spina bifida or anencephaly. These are important in pregnancies where folic acid and other supplements are not

More info »

Biopharm

Magnetic Targeting of Cells using MR Imaging Gradients

Available for: Co-development and/or licensingSummaryUCL researchers have developed a novel technique to magnetically target cells using MRI. This allows image guided targeted delivery of cells to sites of the body which cannot be reached with external permanent magnets.The Technology and its AdvantagesAn increasing number of clinical trials assess the efficacy of stem cell therapies, with

More info »

Biopharm

Imatinib and other ABL inhibitors to treat ocular neovascularisation

Available for: Exclusive LicensingSummaryRetinal and choroidal diseases are the most common cause of vision loss in the western world. They are either caused by the leakage and neovasculatisation from retinal vessels (diabetic retinopathy, retinal vein occlusions, retinopathy of prematurity and neovascular glaucoma) or by new vessels growing into the retina and subretinal space (AMD, ocular

More info »

External Projects

OpSAFE

Available For: Exclusive or Non-Exclusive licenseSummaryOpSAFE is a medical device that enables touch free use of OsiriX MD image viewer for medical images.The Technology and its AdvantagesFully CE marked, the OpSAFE device comprises plug in software, foot pedal and LEAP motion controller. Staff can remain scrubbed in and there is no need for an additional

More info »

View by:

Technology area:
Theme:
Market:
Search: